Xwell Inc. reported its first-quarter 2025 financial results, revealing a total revenue of approximately $7.0 million, down from $8.7 million in the same quarter of 2024. This decline was primarily attributed to lower revenue from XpresTest and XpresSpa, partially offset by a new revenue stream from Priority Pass. The operating loss for the quarter increased to about $3.2 million from $2.4 million in the previous year's first quarter. Additionally, the net loss attributable to XWELL rose to approximately $4.7 million, compared to $2.5 million in the first quarter of 2024. This increase in net loss was largely due to higher-than-normal one-time expenses related to accounting and other non-recurring items. In terms of business operations, Xwell Inc. secured a three-year extension of its Traveler-based Genomic Surveillance Program in partnership with the CDC. The company also successfully closed a private placement in January 2025, raising approximately $4 million from the issuance of Series G Convertible Preferred Stock and Series Warrants. Total cost of sales for the first quarter decreased by about 6% to $5.7 million compared to $6.1 million in the previous year, and total operating expenses decreased by approximately 11% to $4.5 million from $5.1 million in the same quarter last year. Despite the challenges, Xwell Inc. remains focused on returning to overall profitability in the future.